Evaluation of mono and combined nitrofurantoin therapy for toxoplasmosis in vivo using murine model

References

• Fanfan S, Lan J, Haibin Z, et al. Synthesis and anti-Toxoplasma activity in Vitro of chrysin derivatives. Chin J Org Chem. 2019;39(9):2574–2580.
   Web of Science ®Google Scholar
• Jones JL, Parise ME, Fiore AE. Neglected parasitic infections in the United States: toxoplasmosis. Am J Trop Med Hyg. 2014;90(5):794–799.
   PubMed Web of Science ®Google Scholar
• Shammaa AM, Powell TG, Benmerzouga I. Adverse outcomes associated with the treatment of Toxoplasma infections. Sci Rep. 2021;11(1):1035.
   PubMed Web of Science ®Google Scholar
• McAuley JB. Congenital Toxoplasmosis. J Pediatric Infect Dis Soc. 2014;3(Suppl 1):S30–35.
   PubMedGoogle Scholar
• Daher D, Shaghlil A, Sobh E, et al. Comprehensive overview of Toxoplasma gondii-induced and associated diseases. Pathogens. 2021;10(11):1351.
   PubMed Web of Science ®Google Scholar
• Abd El-Rehim El-Henawy A, Abdel-Razik A, Zakaria S, et al. Is toxoplasmosis a potential risk factor for liver cirrhosis? Asian Pac J Trop Med. 2015;8(10):784–791.
   PubMed Web of Science ®Google Scholar
• Wassef R, Abdel-Malek R. Validity of a new immunochromatographic test in detection of Toxoplasma gondii in cancer patients. J Parasit Dis. 2019;43(1):83–86.
   PubMedGoogle Scholar
• Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis [published correction appears in Clin Microbiol Rev [2012 Jul;25(3)583]. Clin Microbiol Rev. 2012;25(2):264–296. 10.1128/CMR.05013-11
   PubMed Web of Science ®Google Scholar
• Dunay IR, Gajurel K, Dhakal R, et al. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018; 31(4):e00057–17. DOI:10.1128/CMR.00057-17.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–1976.
   PubMed Web of Science ®Google Scholar
• Megged O, Shalit I, Yaniv I, et al. Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation. Pediatr Transplant. 2008;12(8):902–905.
   PubMed Web of Science ®Google Scholar
• Montazeri M, Sharif M, Sarvi S, et al. A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006-2016). Front Microbiol. 2017;8:25.
   PubMedGoogle Scholar
• Al-Zanbagi NA. Effectiveness of myrrh and spiramycin as inhibitors for Toxoplasma Gondii tachyzoites in Vivo. MJFMCT. 2007;15(2):117–128.
   Google Scholar
• Al-Zanbagi NA. In vivo effect of some home spices extracts on the Toxoplasma Gondii tachyzoites. J Family Community Med. 2009;16(2):59–65.
   PubMedGoogle Scholar
• Rayan HZ, Wagih HM, Atwa MM. Efficacy of black seed oil from nigella sativa against murine infection with cysts of Me49 strain of Toxoplasma gondii PUJ. 2011;4:165–176.
   Google Scholar
• Melo E, Vilela K, Carvalho C. Effects of aqueous leaf extracts of Azadirachta Indica A. Juss. (neem) and Melia azedarach L. (Santa Barbara or cinnamon) on the intracellular development of. J Obstet Gynaecol. 2011;13(2):215–222.
   Google Scholar
• Choi W, Jiang M, Chu J. Antiparasitic effects of Zingiber officinale (Ginger) extract against Toxoplasma gondii. J Applied Biomed. 2013;11(1):15–26.
   Web of Science ®Google Scholar
• Kannigadu C, N’Da DD. Recent advances in the synthesis and development of nitroaromatics as anti-infective drugs. Curr Pharm Des. 2020;26(36):4658–4674.
   PubMed Web of Science ®Google Scholar
• Kaiser M, Mäser P, Tadoori LP, et al. Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning. PLoS One. 2015;10(8):e0135556.
   PubMed Web of Science ®Google Scholar
• Yeo SJ, Jin C, Kim S, et al. In Vitro and in Vivo effects of nitrofurantoin on experimental toxoplasmosis. Korean J Parasitol. 2016;54(2):155–161.
   PubMed Web of Science ®Google Scholar
• Djurkovic Djakovic O, Milenkovic V. Murine model of drug-induced reactivation of Toxoplasma gondii. Acta Protozool. 2001;40:99–106.
   Web of Science ®Google Scholar
• El-Shafey AAM, Hegab MHA, Seliem MME, et al. Curcumin@metal organic frameworks nano-composite for treatment of chronic toxoplasmosis. J Mater Sci. 2020;31(11):90.
   Web of Science ®Google Scholar
• Nasr ME, Abdel Hamid AH, Aly NSM, et al. Efficacy of azithromycin on experimental toxoplasmosis infected mice. J Egypt Soc Parasitol. 2020;50(2):293–299.
   Google Scholar
• Bancroft JD, Stevens A, Turner DR. Theory and practice of histological techniques. 4th ed. New York: Churchill Livingstone; 1996.
   Google Scholar
• Contini C, Seraceni S, Cultrera R, et al. Evaluation of a real-time PCR-based assay using the lightcycler system for detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients with toxoplasmic retinochoroiditis. Int J Parasitol. 2005;35(3):275–283.
   PubMed Web of Science ®Google Scholar
• Konstantinovic N, Guegan H, Stäjner T, et al. Treatment of toxoplasmosis: current options and future perspectives [published correction appears in food waterborne parasitol. Food Waterborne Parasitol. 2020;2019(15):e00036. [2020 Dec 15;21:e00105]. 10.1016/j.fawpar.2019.e00036
   Google Scholar
• Benmerzouga I, Checkley LA, Ferdig MT, et al. Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. Antimicrob Agents Chemother. 2015;59(11):6939–6945.
   PubMed Web of Science ®Google Scholar
• Sharma S, Anand N. Approaches to design and synthesis of antiparasitic drugs. Amsterdam: Elsevier; 1997.
   Google Scholar
• Foster R, Pringle G, King DF, et al. The therapeutic activity of some nitrofurans in experimental filariasis and trypanosomiasis. Ann Trop Med Parasitol. 1969;63(1):95–107.
   PubMed Web of Science ®Google Scholar
• Szabo EK, Finney CAM. Toxoplasma gondii: one organism, multiple models. Trends Parasitol. 2017;33(2):113–127.
   PubMed Web of Science ®Google Scholar
• Habib FA. Post-treatment assessment of acute Toxoplasma infection during pregnancy. J Obstet Gynaecol. 2008;28(6):593–595.
   PubMedGoogle Scholar
• Martínez-Gómez F, García-González LF, Mondragón-Flores R, et al. Protection against Toxoplasma gondii brain cyst formation in mice immunized with Toxoplasma gondii cytoskeleton proteins and Lactobacillus casei as adjuvant. Vet Parasitol. 2009;160(3–4):311–315.
   PubMed Web of Science ®Google Scholar
• Clemente M, Curilovic R, Sassone A, et al. Production of the main surface antigen of Toxoplasma gondii in tobacco leaves and analysis of its antigenicity and immunogenicity. Mol Biotechnol. 2005;30(1):41–50.
   PubMed Web of Science ®Google Scholar
• Maddison J, Page S, Church D. Small animal clinical pharmacology. Edinburgh: Saunders Elsevier; 2009.
   Google Scholar
• Gerpe A, Alvarez G, Benítez D, et al. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg Med Chem. 2009;17(21):7500–7509.
   PubMed Web of Science ®Google Scholar
• Remington J. Infectious diseases of the fetus and newborn infant. Philadelphia: Elsevier Saunders; 2006.
   Google Scholar
• Munsimbwe L, Seetsi A, Namangala B, et al. In vitro and In vivo trypanocidal efficacy of synthesized nitrofurantoin analogs. Molecules. 2021;26(11):3372.
   PubMed Web of Science ®Google Scholar
• Payne AJ, Neal LM, Knoll LJ. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res. 2013;112(11):3859–3863.
   PubMed Web of Science ®Google Scholar
• Bennett J, Dolin R, Blaser M. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 9th ed. Vol. 2. Philadelphia, PA: Elsevier; 2019.
   Google Scholar